Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Mark Wilterding; Mark Wilterding Senior Vice President, Investor Relations and Treasurer; Edwards Lifesciences Corp. Bernard Zovighian; President, Chief Executive Of ...

Anteris Technologies Global Corp.’s AVR share price has dipped by 5.20%, which has investors questioning if this is right ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Piper Sandler upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $80, up from $73. The firm sees a “better ...

In more serious cases, aortic valve replacement may be the best option. This can be done with traditional, open-heart surgery or with a relatively newer procedure known as transcatheter aortic ...